Skip to main content
0
Introduction
Aim
Methods
Results
Conclusions
References
Disclosures
Slide deck
Contents
Aim
To assess the effect of nintedanib on the rate of decline in FVC in subjects with differing FVC at baseline in the INBUILD trial.
×
Notice
This website is intended for healthcare professionals only.
Modal title
You are navigating away from the website. Are you sure you want to proceed?
